Krystal Biotech KRYS
NASDAQ KRYS
$335.06 -2.02 (-0.60%)
At close: Sep 29, 2026 · 4:00 PM EDT

Krystal Biotech (KRYS) EV to EBITDA (2024 - 2026)

Updated

Krystal Biotech's (KRYS) EV to EBITDA was 49.87 for Q2 2026, up 119.4% from 22.73 a year earlier and up 35.7% from the prior quarter.

Analysis

Krystal Biotech (KRYS) EV to EBITDA (2024 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Krystal Biotech's EV to EBITDA came in at 38.17, up 270.8% year-over-year; for FY2025, it was 38.13, down 30.1% from FY2024.

  • By year, EV to EBITDA came in at 54.54 in FY2024.
  • The Q2 2026 figure ranks as the highest quarterly EV to EBITDA since Q4 2024.
  • Year over year, EV to EBITDA gained in 1 of the last four quarters, with growth averaging 0.1%.
  • Per Business Quant data, the three quarters before Q2 2026 came in at 36.76 (Q1 2026), 38.16 (Q4 2025) and 26.76 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Krystal Biotech 9.98 Bn 6.75 Bn 112.79 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 49.87
Mar 31, 2026 36.76
Dec 31, 2025 38.16
Sep 30, 2025 26.76
Jun 30, 2025 22.73
Mar 31, 2025 40.09
Dec 31, 2024 54.62
Sep 30, 2024 138.14
API Access

Krystal Biotech EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=KRYS&period=max&api_key=YOUR_API_KEY